Breaking News, Collaborations & Alliances

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

Paves the way towards getting OCU200 in the clinic by first half of 2022.

By: Contract Pharma

Contract Pharma Staff

Ocugen, a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, has entered into an agreement with Kemwell Biopharma to manufacture OCU200, Ocugen’s novel biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD).   Kemwell will manage all CMC and clinical manu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters